Cipher Pharmaceuticals Inc Total Liabilities
Cipher Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Cipher Pharmaceuticals Inc (CPH) has total liabilities worth CA$19.60 Million CAD (≈ $14.18 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Cipher Pharmaceuticals Inc (CPH) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cipher Pharmaceuticals Inc (2004–2025)
Total liabilities of Cipher Pharmaceuticals Inc from 2004 to 2025. This chart illustrates how Cipher Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Cipher Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Cipher Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Cipher Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boryszew SA
WAR:BRS
|
Poland | zł2.21 Billion |
|
White Gold Corp
V:WGO
|
Canada | CA$16.12 Million |
|
Bpost NV
BR:BPOST
|
Belgium | €4.74 Billion |
|
Leenos Corp
KQ:039980
|
Korea | ₩11.99 Billion |
|
SIM Acquisition Corp. I Unit
NASDAQ:SIMAU
|
USA | $10.95 Million |
|
FPT Securities JSC
VN:FTS
|
Vietnam | ₫10.12 Trillion |
|
Hagag Europe Development ZF Ltd
TA:HGGE
|
Israel | ILA231.81 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Cipher Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CPH total assets.
Liquidity & Leverage Metrics
Cipher Pharmaceuticals Inc Total Liabilities Ratios Explained
Cipher Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cipher Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cipher Pharmaceuticals Inc (2004–2025)
The table below shows the annual total liabilities of Cipher Pharmaceuticals Inc from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$30.20 Million ≈ $21.85 Million |
-49.80% |
| 2024-12-31 | CA$60.17 Million ≈ $43.53 Million |
+991.80% |
| 2023-12-31 | CA$5.51 Million ≈ $3.99 Million |
-43.16% |
| 2022-12-31 | CA$9.70 Million ≈ $7.01 Million |
-23.98% |
| 2021-12-31 | CA$12.75 Million ≈ $9.23 Million |
+9.63% |
| 2020-12-31 | CA$11.63 Million ≈ $8.42 Million |
-36.92% |
| 2019-12-31 | CA$18.44 Million ≈ $13.34 Million |
-40.36% |
| 2018-12-31 | CA$30.93 Million ≈ $22.37 Million |
-23.06% |
| 2017-12-31 | CA$40.19 Million ≈ $29.08 Million |
-32.32% |
| 2016-12-31 | CA$59.39 Million ≈ $42.96 Million |
+7.23% |
| 2015-12-31 | CA$55.39 Million ≈ $40.07 Million |
+1126.12% |
| 2014-12-31 | CA$4.52 Million ≈ $3.27 Million |
-71.36% |
| 2013-12-31 | CA$15.77 Million ≈ $11.41 Million |
+64.30% |
| 2012-12-31 | CA$9.60 Million ≈ $6.94 Million |
+89.96% |
| 2011-12-31 | CA$5.05 Million ≈ $3.66 Million |
+7.55% |
| 2010-12-31 | CA$4.70 Million ≈ $3.40 Million |
+27.61% |
| 2009-12-31 | CA$3.68 Million ≈ $2.66 Million |
+33.79% |
| 2008-12-31 | CA$2.75 Million ≈ $1.99 Million |
-10.39% |
| 2007-12-31 | CA$3.07 Million ≈ $2.22 Million |
+242.85% |
| 2006-12-31 | CA$895.68K ≈ $647.92K |
-69.92% |
| 2005-12-31 | CA$2.98 Million ≈ $2.15 Million |
-57.48% |
| 2004-12-31 | CA$7.00 Million ≈ $5.07 Million |
-- |
About Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead… Read more